PolynovoCALZF 74 EV-to-FCF is 127.93 as of Jun. 29, 2026. GuruFocus rates CALZF with a GF Score™ of 74/100 and a GF Value™ of $2.21 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 418 Medical Devices & Instruments companies, Polynovo ranks worse than 88.28% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Polynovo's Enterprise Value is $426.13 Mil.
Polynovo's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $3.33 Mil. Therefore, Polynovo's EV-to-FCF for today is 127.93.
The historical rank and industry rank for Polynovo's EV-to-FCF or its related term are showing as below:
CALZF'
s EV-to-FCF Range Over the Past 10 Years
Min: -665.63 Med: -89 Max: 2317.17
Current: 119.9
During the past 13 years, the highest EV-to-FCF of Polynovo was 2317.17. The lowest was -665.63. And the median was -89.00.
CALZF's EV-to-FCF is ranked worse than 88.28% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 22.765
vs CALZF: 119.90
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Polynovo's share price for today is $0.62.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Polynovo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Polynovo EV-to-FCF Related Terms
Polynovo EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Polynovo's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Polynovo's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Polynovo's EV-to-FCF falls into.
Polynovo's current Enterprise Value is $426.13 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Polynovo's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $3.33 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo (CALZF) has a EV-to-FCF of 127.93 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Polynovo and its competitors. According to the industry distribution chart, Polynovo ranks #369 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 88.3%.
Is Polynovo's EV-to-FCF too high?
Polynovo's current EV-to-FCF is 127.93. The Medical Devices & Instruments industry median EV-to-FCF is 22.77. Polynovo's value of 127.93 is 462% above this industry median. Based on the distribution chart, Polynovo ranks #369 out of 418 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Polynovo has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #369 out of 418 companies for EV-to-FCF. This places Polynovo in the lower half of its industry. The industry median EV-to-FCF is 22.77. Polynovo's value of 127.93 is 462% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.77, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current EV-to-FCF of 127.93 is 462% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Polynovo and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current EV-to-FCF is 127.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.21, compared to a current price of $0.62 — trading 71.9% below its estimated fair value. The current EV-to-FCF is 127.93 and 462% above the Medical Devices & Instruments industry median of 22.77. Polynovo's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Polynovo (CALZF), the current EV-to-FCF is 127.93 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (CALZF) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of $0.62 is trading 71.9% below its estimated GF Value™ of $2.21.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for CALZF:
EV-to-FCF: 127.93
GF Value™: $2.21 vs. price of $0.62 (71.9% below fair value)
Industry Position: 462% above the Medical Devices & Instruments median (#369 of 418)
No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
74GF Score
Get the complete analysis for CALZF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALZF has been successfully added to your 
